CN101102786A - 施用并利用vegf抑制剂治疗人类癌症的方法 - Google Patents

施用并利用vegf抑制剂治疗人类癌症的方法 Download PDF

Info

Publication number
CN101102786A
CN101102786A CNA2005800189582A CN200580018958A CN101102786A CN 101102786 A CN101102786 A CN 101102786A CN A2005800189582 A CNA2005800189582 A CN A2005800189582A CN 200580018958 A CN200580018958 A CN 200580018958A CN 101102786 A CN101102786 A CN 101102786A
Authority
CN
China
Prior art keywords
cancer
vegf
use according
flt
initial dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800189582A
Other languages
English (en)
Chinese (zh)
Inventor
J·M·塞德鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN101102786A publication Critical patent/CN101102786A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CNA2005800189582A 2004-06-10 2005-06-10 施用并利用vegf抑制剂治疗人类癌症的方法 Pending CN101102786A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57849904P 2004-06-10 2004-06-10
US60/578,499 2004-06-10

Publications (1)

Publication Number Publication Date
CN101102786A true CN101102786A (zh) 2008-01-09

Family

ID=35510259

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800189582A Pending CN101102786A (zh) 2004-06-10 2005-06-10 施用并利用vegf抑制剂治疗人类癌症的方法

Country Status (9)

Country Link
US (7) US7354580B2 (https=)
EP (2) EP1753442A2 (https=)
JP (2) JP2008502738A (https=)
CN (1) CN101102786A (https=)
AU (1) AU2005254058A1 (https=)
CA (1) CA2567686A1 (https=)
IL (1) IL179515A0 (https=)
MX (1) MXPA06014421A (https=)
WO (1) WO2005123104A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102265157A (zh) * 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断用途的方法和组合物
CN104004058A (zh) * 2014-06-23 2014-08-27 苏州普罗达生物科技有限公司 有关白介素-33抑制剂多肽及其应用
CN108496084A (zh) * 2016-01-25 2018-09-04 赛诺菲 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06014689A (es) * 2004-06-18 2008-03-11 Regeneron Pharma Inhibidores del vegf para el tratamiento de efusion pleural maligna.
ES2633574T3 (es) * 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
CA2615636A1 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
JP2009537606A (ja) * 2006-05-25 2009-10-29 ノバルティス アクチエンゲゼルシャフト チロシンキナーゼ阻害剤
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
HUE029445T2 (en) * 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
SG187012A1 (en) * 2010-07-19 2013-02-28 Hoffmann La Roche Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe
MX368442B (es) * 2014-01-25 2019-10-02 Chengdu Kanghong Biotechnologies Co Ltd Proteína de fusión que inhibe angiogénesis o crecimiento y uso de la misma.
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
WO2016077227A2 (en) * 2014-11-14 2016-05-19 Genentech, Inc. Predicting response to a vegf antagonist
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US10947537B2 (en) * 2016-02-18 2021-03-16 University Of Massachusetts Method of treating VEGF/VEGFR resistant prostate cancer by combining the therapy with RAC1 inhibitors
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
EP3664803A4 (en) * 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
WO2019083172A1 (ko) * 2017-10-24 2019-05-02 국립암센터 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
AU2019212622B2 (en) 2018-01-26 2024-05-23 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
WO2020106049A1 (ko) * 2018-11-20 2020-05-28 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성
KR20200094110A (ko) * 2019-01-29 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물
WO2020159171A2 (ko) * 2019-02-01 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
BR112022010113A2 (pt) 2019-11-25 2022-09-06 Univ California Inibidores de vegf de longa ação para neovascularização intraocular
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US20220196166A1 (en) * 2020-12-18 2022-06-23 Nibco Inc. L-ball union drain valve
US11898643B1 (en) 2022-12-28 2024-02-13 Nibco Inc. Dual union ball drain valve with T-flow adjustability
US12140236B2 (en) 2023-02-08 2024-11-12 Nibco Inc. Dual union drain valve with reversible check inserts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN101433715B (zh) * 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
CA2519835A1 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
WO2004110490A2 (en) 2003-06-06 2004-12-23 Regeneron Pharmaceuticals, Inc. Use of vegf inhibitors for tumor regression

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102265157A (zh) * 2008-12-23 2011-11-30 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断用途的方法和组合物
CN102265157B (zh) * 2008-12-23 2014-11-26 霍夫曼-拉罗奇有限公司 用于癌症患者中诊断用途的方法和组合物
CN104004058A (zh) * 2014-06-23 2014-08-27 苏州普罗达生物科技有限公司 有关白介素-33抑制剂多肽及其应用
CN108496084A (zh) * 2016-01-25 2018-09-04 赛诺菲 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法

Also Published As

Publication number Publication date
JP2008502738A (ja) 2008-01-31
WO2005123104A2 (en) 2005-12-29
US7479273B2 (en) 2009-01-20
EP1753442A2 (en) 2007-02-21
US7482002B2 (en) 2009-01-27
US20080214465A1 (en) 2008-09-04
WO2005123104A3 (en) 2006-04-27
US20050276808A1 (en) 2005-12-15
US20080214466A1 (en) 2008-09-04
US20080188419A1 (en) 2008-08-07
EP2583685A1 (en) 2013-04-24
CA2567686A1 (en) 2005-12-29
US7354580B2 (en) 2008-04-08
IL179515A0 (en) 2007-05-15
AU2005254058A1 (en) 2005-12-29
US7479272B2 (en) 2009-01-20
US7479275B2 (en) 2009-01-20
JP2012067116A (ja) 2012-04-05
US20080188420A1 (en) 2008-08-07
US20080188418A1 (en) 2008-08-07
MXPA06014421A (es) 2007-05-04
US7479274B2 (en) 2009-01-20
US20080171703A1 (en) 2008-07-17
US7482001B2 (en) 2009-01-27

Similar Documents

Publication Publication Date Title
CN101102786A (zh) 施用并利用vegf抑制剂治疗人类癌症的方法
US10981973B2 (en) Methods of treating a sclerotic disorder by administering a transforming growth factor beta receptor type II fusion polypeptide
KR101718748B1 (ko) Ｉｌ-6 수용체의 길항에 의한 종양 성장의 저해 방법
KR102338453B1 (ko) Ｖｅｇｆ 길항제와 항-ｃｔｌａ-4 항체의 조합물을 포함하는 조성물 및 방법
KR101175990B1 (ko) Ｖｅｇｆ 길항제와 항증식성 제제의 조성물
CN113171442B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
KR101774272B1 (ko) Ｗｎｔ 길항약 및 치료와 스크리닝 방법
KR102079482B1 (ko) 비효율적 적혈구생성 치료를 위한 방법 및 조성물
US20040265309A1 (en) Method of tumor regression with VEGF inhibitors
KR101819135B1 (ko) 당화 vegf 디코이 수용체 융합 단백질
KR20080033390A (ko) Ｖｅｇｆ 길항제로 질병을 치료하는 방법
CN1968709A (zh) 用于治疗恶性胸腔积液的vegf抑制剂
KR20120049214A (ko) 발열성 지방세포를 증가시키는 방법
TW201010715A (en) FGF21 mutants and uses thereof
KR20150082327A (ko) Ｄｌｌ4 길항제로 난소암을 치료하는 방법
CN1997386A (zh) 通过阻断vegf介导的活性来治疗i型糖尿病的方法
HK1116053A (zh) 施用并利用vegf抑制剂治疗人类癌症的方法
AU2022221660A1 (en) Multi-domain fusion protein and use thereof
HK1224576A1 (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
CA2952231A1 (en) Formulated receptor polypeptides and related methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1116053

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080109

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1116053

Country of ref document: HK